Sonnet BioTherapeutics Holdings (SONN) said Monday its phase 1 trial of SON-1010 demonstrated a partial response and disease stabilization in adult patients with advanced solid tumors.
One patient in the highest-dose cohort experienced a 45% tumor reduction per RECIST criteria, while 48% of evaluable patients maintained stability at four months, the company said.
No dose-limiting toxicities or related serious adverse events have been reported, with most adverse events being mild and transient, Sonnet said.
Shares of the company surged nearly 116% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments